CMPS241220C2500
- 2.20
- 0.000.00%
COMPASS Pathways Newsroom
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
Express News | U.S.-Listed Shares of ATAI Life Sciences up 9.1%
Express News | GH Research Shares up 4.1%
Express News | Compass Pathways Shares up 11.9%
Express News | Shares of Psychedelic Drug Developers Rise After Rfk Jr Picked for Top US Health Agency Role
RFK and the 'MAHA Trade': Vaccine Makers Down, Psychedelic Shares up
Compass Pathways to Participate in Stifel 2024 Healthcare Conference
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
Strategic Opportunity in COMPASS Pathways Amid Extended Phase 3 Trials and Conservative Price Target
Massachusetts Psychedelics Legalization Initiative Poised to Fail
Top 3 Health Care Stocks You'll Regret Missing In November
BTIG Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $12
Morgan Stanley Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $17
Massachusetts may become the next stop for legalization, is it a good investment opportunity for psychedelic drug concept stocks?
On Tuesday, Massachusetts voters will decide whether the state will legalize psilocybin, a hallucinogenic compound found in "magic mushrooms," worth noting for related concept stocks.
Legalizing Psychedelics: Is Massachusetts Next?
Compass Pathways Is Maintained at Outperform by RBC Capital
Compass Pathways Analyst Ratings
Maxim Group Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Cuts Target Price to $12
A Quick Look at Today's Ratings for COMPASS Pathways(CMPS.US), With a Forecast Between $12 to $23